AT
Amplia Therapeutics Limited
ATX.AX · ASX
$0.13 +0.00% (+$0.00)
1M -7.14%
Market Cap $66.7M
P/E Ratio -
Div. Yield -
ROE 22.62%
Piotroski F-Score Weak
1/9Valuation
32 /100
Expensive P/B 3.17x
P/S 17.64x
EV/EBITDA N/A
Growth
82 /100
Growing Book val. growth 1.27%
Rev. growth 24.02%
FCF growth N/A
Profitability
20 /100
Weak Net margin 173.69%
Op. margin 172.22%
FCF margin 182.04%
Quality
2 /100
Poor ROE 22.62%
ROA 28.65%
Asset turnover 0.16x
Debt
69 /100
Low Current ratio 7.91x
Int. coverage -121.54x
Debt/Equity 0.00x
Stability
34 /100
Moderate Rev. volatility 174.73%
EPS volatility 28.77%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre ATX.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher J. Burns
Employees
8
Headquarters
Melbourne
Evenimente viitoare
27 NOV.
Earnings
Upcoming earnings report